Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 433 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Transplant Recipients Clear all
Terminated Phase 2 Interventional

24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients

NCT00555789
View directory record Official record
Conditions
Kidney Transplantation
Interventions
AEB071, mycophenolic plus tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

NCT00782821
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Rabbit Antithymocyte Globulin, Velcade, Rituxan
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 14, 2026, 8:22 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

NCT06568549
View directory record Official record
Conditions
Kidney Transplantation, Mycophenolate Mofetil
Interventions
Mycophenolate Mofetil (MMF) Maintenance Group, Mycophenolate Mofetil (MMF) Withdrawal Group
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients

NCT01288521
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus + Ketoconazole, Then Tacrolimus alone, Tacrolimus alone, Then Tacrolimus + Ketoconazole
Drug
Lead sponsor
Sony Tuteja
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 14, 2026, 8:22 AM EDT
Completed No phase listed Observational

Biomarkers of Aging as Predictors of Kidney Transplant Function

NCT02335333
View directory record Official record
Conditions
Delayed Graft Function, Other Complications of Kidney Transplant
Interventions
No treatment
Other
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 14, 2026, 8:22 AM EDT
Completed No phase listed Observational

Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL

NCT03263052
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Tacrolimus XR (Envarsus)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

Sirolimus Conversions in African-American Renal Transplant Recipients

NCT01005706
View directory record Official record
Conditions
Absence; Kidney
Interventions
rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 14, 2026, 8:22 AM EDT
Withdrawn No phase listed Observational

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

NCT00203281
View directory record Official record
Conditions
Kidney Transplantation, Plasmapheresis
Interventions
tacrolimus, mycophenolate mofetil, daclizumab, intravenous immune globulin, plasmapheresis
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 14, 2026, 8:22 AM EDT
Completed No phase listed Observational

Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

NCT05238220
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
Valganciclovir
Drug
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 14, 2026, 8:22 AM EDT
Recruiting No phase listed Observational

Immune Registry for BK in Kidney Transplant Recipients

NCT06538961
View directory record Official record
Conditions
BK Virus Infection, Kidney Transplant; Complications
Interventions
Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group, Urine sample- Sub-study group, Blood sample: Sub-study group
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 8:22 AM EDT
Terminated Phase 2 Interventional

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 14, 2026, 8:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Carfilzomib and Belatacept for Desensitization

NCT05017545
View directory record Official record
Conditions
Highly Sensitized Prospective Kidney Transplant Recipients
Interventions
carfilzomib, belatacept, Bone marrow aspiration
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 14, 2026, 8:22 AM EDT
Withdrawn Not applicable Interventional

Transversus Abdominis Plane (TAP) Block After Kidney Transplantation

NCT01496729
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Transversus abdominis plane (TAP) block, Sham TAP block with normal saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Phase 3 Interventional

A Multivitamin Comparison Study in Kidney Transplant Recipients.

NCT00217100
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Multivitamin, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 14, 2026, 8:22 AM EDT
Terminated Not applicable Interventional

Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients

NCT00235781
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Thymoglobulin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2006 · Synced Oct 14, 2026, 8:22 AM EDT
Withdrawn Phase 4 Interventional

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

NCT05275907
View directory record Official record
Conditions
High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions
Amlodipine Besylate, Chlorthalidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Phase 2 Interventional Results available

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

NCT00483756
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
37
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

NCT01491919
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril
Drug
Lead sponsor
Uptal Patel
Other
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 14, 2026, 8:22 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT04225988
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Extended-release tacrolimus, Immediate-release tacrolimus
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

NCT00007787
View directory record Official record
Conditions
Kidney Transplantation, Chronic Allograft Nephropathy
Interventions
Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 14, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients

NCT02763943
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Medication Adherence
Interventions
Pharmacist-led, technology enabled education intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 14, 2026, 8:22 AM EDT
Not listed Phase 1 Interventional

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

NCT03791476
View directory record Official record
Conditions
Kidney Failure
Interventions
rhC1INH, Saline Solution
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 14, 2026, 8:22 AM EDT